Scilex Holding (SCLX) Net Cash Flow Growth (3y) (2023 - 2026)
Scilex Holding (SCLX) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 37.67% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -129.17% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -10.13% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.96% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -51.84% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 8.91% |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -27.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.69% |
| Dec 31, 2025 | 162.66% |
| Sep 30, 2025 | 9.60% |
| Jun 30, 2025 | 59.55% |
| Mar 31, 2025 | -55.24% |
| Dec 31, 2024 | -102.18% |
| Sep 30, 2024 | 77.73% |
| Jun 30, 2024 | 211.92% |
| Mar 31, 2024 | -107.03% |
| Dec 31, 2023 | 348.30% |
| Sep 30, 2023 | -650.24% |